SCHEMBL2010768

SCHEMBL2010768

O=C(Cc1cc(Br)ccn1)c1ccc(F)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.61
PTPN1 P18031 1/20 0.46
NPC1 O15118 3/20 0.43
KMT2A Q03164 4/20 0.43
MEN1 O00255 2/20 0.43
ATM Q13315 1/20 0.43
ALDH1A1 P00352 4/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM4E B2RXH2 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HTR7 P34969 1/20 0.38
PLOD2 O00469 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
LTA4H P09960 1/20 0.38
CXCR2 P25025 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2010007 0.85 ALDH1A1 (0.49) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL5214600 0.85 RAB9A (0.61) RAB9APTPN1NPC1KMT2AMEN1
SCHEMBL2010817 0.85 RAB9A (0.61) RAB9ANPC1KMT2AALDH1A1KDM4E
SCHEMBL15489237 0.84 RAB9A (0.49) RAB9APTPN1NPC1KMT2AMEN1
SCHEMBL12465723 0.81 GSK3B (0.50) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL2008367 0.79 RAB9A (0.38) RAB9APTPN1KMT2AMEN1ATM
SCHEMBL12544105 0.79 RAB9A (0.38) RAB9APTPN1KMT2AMEN1ATM
SCHEMBL3020768 0.78 L3MBTL1 (0.50) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL16847893 0.77 LMNA (0.44) RAB9APTPN1NPC1KMT2AMEN1
SCHEMBL6598838 0.76 RAB9A (1.00) RAB9APTPN1NPC1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2477990-B1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-08-20 EP disclosed
US-8680096-B2 Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators SANOFI-AVENTIS (FR) 2014-03-25 US disclosed
US-8618301-B2 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof SANOFI (FR) 2013-12-31 US disclosed
US-8546424-B2 Acetylene derivatives of 5-phenyl-pyrazolopyridine, preparation thereof, and therapeutic use thereof SANOFI (FR) 2013-10-01 US disclosed
EP-2507238-B1 DIPHENYL-PYRAZOLOPYRIDINE COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MODULATORS OF THE NUCLEAR RECEPTOR NOT SANOFI SA (FR) 2013-07-31 EP disclosed
EP-2477988-B1 Acetylenic derivatives of 5-phenyl-pyrazolopyridine, process for their preparation and therapeutic use thereof SANOFI SA (FR) 2013-07-17 EP disclosed
US-20130023554-A1 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-01-24 US disclosed
US-20120270897-A1 ACETYLENE DERIVATIVES OF 5-PHENYL-PYRAZOLOPYRIDINE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-10-25 US disclosed
EP-2507238-A1 DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS SANOFI (FR) 2012-10-10 EP disclosed
US-20120245164-A1 DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS SANOFI (FR) 2012-09-27 US disclosed
EP-2477990-A1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-07-25 EP disclosed
EP-2477988-A1 ACETYLENE DERIVATIVES OF 5-PHENYL-PYRAZOLOPYRIDINE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-07-25 EP disclosed
WO-2011067544-A1 DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS SANOFI-AVENTIS (FR) 2011-06-09 WO disclosed
WO-2011033230-A1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270897-A1 ACETYLENE DERIVATIVES OF 5-PHENYL-PYRAZOLOPYRIDINE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF NAT1, KCNH1, PC RAB9A 2004/4885PTPN1 3887/4885NPC1 1445/4885
US-20120245164-A1 DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS NR4A3, NCOR1, NR4A2 RAB9A 3336/4885PTPN1 936/4885NPC1 867/4885
US-20130023554-A1 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF CBR3, CBR1, OGFR RAB9A 1236/4885PTPN1 1373/4885NPC1 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.